Internal Medicine · Greensburg, PA
NPI
1366448508
Since 2005
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
426 Pellis Rd, Suite 1
Greensburg, PA, 15601
Phone (724) 832-7632
Groups this clinician bills Medicare through
Medicare paid, 2024
$132K
1,144 services
Medicare patients, 2024
477
Average age 72
Drug cost, 2024
$1.7M
3,438 prescriptions
Company payments, 2025
$1,471
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bharat Jain was code 99213 (office e&m - established), 505 times for 413 patients. In total Bharat Jain billed 1,144 services in 14 codes, and Medicare paid $132K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-10-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 505 | 413 | $60.34 | $30K |
| 94060 Pulmonary Function Testing | Office | 109 | 108 | $28.04 | $3,057 |
| 94729 Pulmonary Function Testing | Office | 107 | 106 | $42.16 | $4,511 |
| 94726 Pulmonary Function Testing | Office | 106 | 105 | $42.30 | $4,483 |
| 95811 Sleep Study | Office | 103 | 102 | $493.39 | $51K |
| 99203 Office E&M - New | Office | 56 | 56 | $71.88 | $4,025 |
| 95810 Sleep Study | Office | 51 | 48 | $468.31 | $24K |
| 99214 Office E&M - Established | Office | 50 | 38 | $85.15 | $4,257 |
| 99204 Office E&M - New | Office | 32 | 32 | $123.97 | $3,967 |
| 95800 Sleep Study | Office | 13 | 13 | $90.15 | $1,172 |
By year: 2022 $124K for 1,144 services; 2023 $146K for 1,264 services; 2024 $132K for 1,144 services.
Medicare prescription drug claims, 2024
In 2024, the drug Bharat Jain prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 1,369 prescriptions and refills. In total Bharat Jain wrote 3,438 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 1,369 | 1,599 | 241 | $997K |
| Theophylline Er Theophylline Anhydrous | 650 | 862 | 118 | $56K |
| Breo Ellipta Fluticasone/Vilanterol | 281 | 336 | 59 | $128K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 192 | 214 | 56 | $5,066 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 172 | 186 | 47 | $115K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 83 | 91 | 11 | $16K |
| Spiriva Respimat Tiotropium Bromide | 81 | 97 | 15 | $50K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 66 | 68 | 15 | $32K |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 60 | 62 | Under 11 | $29K |
| Armodafinil Generic | 49 | 59 | Under 11 | $2,137 |
| Modafinil Generic | 48 | 54 | Under 11 | $2,128 |
| Ventolin Hfa Albuterol Sulfate | 44 | 54 | Under 11 | $2,971 |
| Prednisone Generic | 43 | 43 | 28 | $104 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 32 | 34 | Under 11 | $3,993 |
| Azithromycin Generic | 30 | 30 | 12 | $45.65 |
Brand drugs: 2,411 claims; generic drugs: 1,027 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bharat Jain $1,471 ($1,471 in general payments such as food, travel and fees) from 17 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $439.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 19 | $439 |
| GlaxoSmithKline, LLC. GSK | 10 | $146 |
| Insmed, Inc. INSM | 8 | $139 |
| Verona Pharma, Inc. VRNA | 9 | $135 |
| Axsome Therapeutics, Inc. AXSM | 6 | $132 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $80.51 |
| Jazz Pharmaceuticals Inc. JAZZ | 3 | $68.29 |
| Harmony Biosciences LLC HRMY | 2 | $56.29 |
| Inspire Medical Systems, Inc. INSP | 2 | $49.72 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $39.4 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.